Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Transplantation. 2017 Jun;101(6):1222–1227. doi: 10.1097/TP.0000000000001330

Figure 2C. No change in cPRA following bortezomib monotherapy.

Figure 2C

There was no significant decrease in cPRA when MFI 2000, 4000, or 8000 used as alloantibody positivity threshold. (*) More than 1 patient had cPRA =100% that was unchanged posttreatment.